Development of an effective polyvalent vaccine against both Marek's and Newcastle diseases based on recombinant Marek's disease virus type 1 in commercial chickens with maternal antibodies.
about
Efficient strategy for constructing duck enteritis virus-based live attenuated vaccine against homologous and heterologous H5N1 avian influenza virus and duck enteritis virus infection.Construction of a recombinant duck enteritis virus vaccine expressing hemagglutinin of H9N2 avian influenza virus and evaluation of its efficacy in ducks.Antigen-Sparing and Enhanced Efficacy of Multivalent Vaccines Adjuvanted with Immunopotentiators in Chickens.Present and future of veterinary viral vaccinology: a review.Complete, long-lasting protection against lethal infectious bursal disease virus challenge by a single vaccination with an avian herpesvirus vector expressing VP2 antigens.Construction of recombinant Marek's disease virus (rMDV) co-expressing AIV-H9N2-NA and NDV-F genes under control of MDV's own bi-directional promoterA duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks.Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tractRecombinant Marek's Disease Virus as a Vector-Based Vaccine against Avian Leukosis Virus Subgroup J in Chicken.Recombinant Marek's disease virus type 1 provides full protection against very virulent Marek's and infectious bursal disease viruses in chickens.Turkey herpesvirus with an insertion in the UL3-4 region displays an appropriate balance between growth activity and antibody-eliciting capacity and is suitable for the establishment of a recombinant vaccine.Efficient strategy to generate a vectored duck enteritis virus delivering envelope of duck Tembusu virusProgress toward the development of polyvalent vaccination strategies against multiple viral infections in chickens using herpesvirus of turkeys as vector
P2860
Q30373912-3A37250E-E889-4535-8E09-48613D36CE73Q30393796-C9DC27E8-5506-452D-8AA5-C025216F305BQ33729299-315E504D-E365-406D-BA49-8D89C9C74B57Q34341579-B8690568-1446-45EB-88F6-C013AC6BB761Q34364428-B210D962-6A48-4992-9BD7-627D577DA288Q35112167-9D92F472-8794-42A9-AE63-710980CE1E8CQ35363479-233E05D5-8BB5-42F6-A53D-23A3470233DEQ36209720-4006CC73-8F9D-44CA-BA3E-468C378D9AFFQ37450167-0A9009F9-9233-4651-A936-62ED26380C9AQ37508539-6D6EC7DE-D0EE-472D-8102-861F43A48C44Q40413599-283D73D0-994F-4A7D-9B5F-BB09E416C43FQ41463338-AA1AE016-C2BA-4423-A568-9A87D656723AQ42174595-EE212B71-A077-458E-92D4-20D45682FA1F
P2860
Development of an effective polyvalent vaccine against both Marek's and Newcastle diseases based on recombinant Marek's disease virus type 1 in commercial chickens with maternal antibodies.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Development of an effective po ...... kens with maternal antibodies.
@en
Development of an effective po ...... kens with maternal antibodies.
@nl
type
label
Development of an effective po ...... kens with maternal antibodies.
@en
Development of an effective po ...... kens with maternal antibodies.
@nl
prefLabel
Development of an effective po ...... kens with maternal antibodies.
@en
Development of an effective po ...... kens with maternal antibodies.
@nl
P2093
P2860
P1433
P1476
Development of an effective po ...... kens with maternal antibodies.
@en
P2093
Kawaguchi Y
Sakaguchi M
Tokiyoshi S
Tokunaga E
Yokogawa K
P2860
P304
P356
10.1128/JVI.74.7.3217-3226.2000
P407
P577
2000-04-01T00:00:00Z